SC-Novartis AG Vs. Union of India

Novartis AG v. Union of India: India's Landmark Stand Against Evergreening of Pharmaceutical Patents

 

Introduction

Few judgments in the history of intellectual property law in India have attracted as much national and international attention as the Supreme Court of India's decision in Novartis AG v. Union of India and Others, reported as (2013) 6 SCC 1, decided on April 1, 2013. This case raised a question that sat at the very crossroads of patent law, public health, access to medicines, and the obligations of a developing nation under international trade agreements. At its heart, the case asked a simple but deeply consequential question: should India grant a patent to a new crystalline form of an already known anti-cancer drug merely because the new form had improved physical properties, even when those improved properties did not translate into a meaningfully better therapeutic outcome for patients?

The drug in question was Gleevec or Glivec, sold by Novartis AG, a Swiss pharmaceutical giant, and used for the treatment of a deadly blood cancer called chronic myeloid leukaemia (CML) as well as certain other tumour-related conditions. The active pharmaceutical ingredient in Gleevec was the beta-crystalline form of Imatinib Mesylate, a compound derived from a broader family of chemical substances. Novartis had been selling Gleevec in India under a price that placed it out of reach for millions of patients. Generic manufacturers, particularly Indian pharmaceutical companies, were producing significantly cheaper versions of the same drug, which allowed patients across India and other developing nations to access life-saving treatment. The patent battle was thus not merely a corporate dispute. It was a contest between the patent rights of a multinational company and the right to life of thousands of cancer patients who depended on affordable medicines.

The case not only tested the limits of India's patent law, particularly the unique provision in Section 3(d) of the Patents Act, 1970 as amended by the Patents (Amendment) Act, 2005, but also examined whether India's approach to pharmaceutical patenting was consistent with its obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) under the World Trade Organization. The Supreme Court, in its unanimous judgment delivered by a Bench of Justices Aftab Alam and Ranjana P. Desai, dismissed Novartis's appeals and refused the patent. The decision sent a clear message to the world: India's patent law, particularly Section 3(d), was not a mere procedural hurdle but a substantive requirement designed to prevent the practice of "evergreening," which is the attempt by pharmaceutical companies to extend their monopoly over a drug by obtaining patents on minor modifications of a known substance without any real therapeutic improvement.

 

Factual and Procedural Background

The origin of this dispute lies in an invention by Dr. Jürg Zimmermann, a scientist who worked for Ciba Geigy (which later merged with Sandoz in 1996 to form Novartis). Dr. Zimmermann invented a family of chemical compounds known as N-phenyl-2-pyrimidine-amine derivatives, which had the property of inhibiting certain tyrosine kinases — enzymes that play a role in the growth of cancer cells. This invention was patented in Europe and in the United States, where it became known as Zimmermann Patent No. 5,521,184, granted by the United States Patent and Trade Mark Office (USPTO) on May 28, 1996. The Zimmermann Patent covered the broad family of compounds, and within that family, the compound specifically identified as Example 21 — later given the international non-proprietary name "Imatinib" — was disclosed, along with its pharmaceutically acceptable salts, including Imatinib Mesylate (the methanesulfonic acid salt of Imatinib).

Novartis subsequently developed Imatinib Mesylate into a drug substance and eventually isolated a specific crystalline form of it — the beta-crystalline form — which it called beta-IM or β-IM. A subsequent US patent, Zimmermann Patent No. 6,894,051 B1, dated May 17, 2005, was granted to Novartis specifically for the beta-crystalline form (β-IM) of Imatinib Mesylate. Novartis marketed the drug under the brand name Gleevec in the United States and Glivec in other countries including India.

In India, Novartis filed a patent application in July 1998 for the beta-crystalline form of Imatinib Mesylate — that is, for β-IM — at the Chennai Patent Office. This application, numbered 1602/MAS/1998, claimed that the beta-crystalline form of Imatinib Mesylate was a new and patentable invention distinct from anything previously disclosed, including the Zimmermann Patent. The application was filed during the period when Indian patent law did not yet allow product patents for pharmaceutical substances, as Section 5 of the Patents Act, 1970 then prohibited product patents for drugs. In 1999, the Indian Government issued an Ordinance that created a "mailbox" mechanism under Article 70.8 of TRIPS, allowing applications for pharmaceutical product patents to be stored and examined once India's obligations to grant such patents under TRIPS kicked in, which happened when the Patents (Amendment) Act, 2005 came into force on January 1, 2005. Novartis's application thus remained in the "mailbox" until the 2005 Amendment opened the door for its examination.

On January 25, 2006, the Assistant Controller of Patents and Designs, Chennai, rejected Novartis's patent application on two main grounds: first, that the compound Imatinib Mesylate was already known from the Zimmermann Patent and was therefore not novel or did not involve an inventive step; and second, that the subject compound, being merely a new form of a known substance with no significantly enhanced efficacy, was excluded from patentability by virtue of Section 3(d) of the amended Patents Act, 1970.

Aggrieved by this rejection, Novartis filed appeals before the Intellectual Property Appellate Board (IPAB), Madras. In the meantime, Novartis also filed a Writ Petition in the High Court of Madras challenging the constitutional validity of Section 3(d) of the Patents Act, arguing that this provision was inconsistent with India's obligations under the TRIPS Agreement and was also vague and arbitrary in violation of Article 14 of the Constitution of India. The High Court, on August 6, 2007, in its decision in Novartis AG v. Union of India, (2007) 4 MLJ 1153, rejected the challenge to Section 3(d)'s constitutionality and its compatibility with TRIPS, holding that Section 3(d) was not violative of any constitutional provision and that TRIPS itself gave member nations the flexibility to define the patentability standards as suited their national interests. The High Court did not, however, deal with the merits of the patent claim itself, leaving those issues for the IPAB.

The IPAB, in its order dated June 26, 2009, partly affirmed the Controller's rejection. The IPAB disagreed with the Controller on the ground of lack of novelty and held that Imatinib Mesylate was not anticipated by the prior art. However, the IPAB upheld the rejection on the ground of Section 3(d), finding that Novartis had failed to demonstrate that β-IM had any significantly enhanced therapeutic efficacy as compared to the known substance Imatinib Mesylate. Novartis and other parties, including Natco Pharma Limited and Cancer Patients Aid Association, all filed appeals before the Supreme Court of India, challenging various aspects of the IPAB's reasoning.

Before the Supreme Court, Civil Appeals Nos. 2706-716 of 2013 (by Novartis), Civil Appeal No. 2728 of 2013 (by Natco Pharma Limited), and Civil Appeals Nos. 2717-27 of 2013 (by Cancer Patients Aid Association) were all heard together. The case thus came to be decided by the Supreme Court with a Bench of Justices Aftab Alam and Ranjana P. Desai.

 

The Dispute

The central legal dispute before the Supreme Court involved the correct interpretation and application of Section 3(d) of the Patents Act, 1970 as amended in 2005, along with Sections 2(1)(j) and 2(1)(ja) defining "invention" and "inventive step" respectively. However, several other important sub-disputes arose in the course of argument.

The first and primary question was whether Imatinib Mesylate — the parent substance from which β-IM was derived — was itself a "new" product when it came into being, or whether it was already a known substance taught by the Zimmermann Patent. This was significant because if Imatinib Mesylate itself was not a "new" product, then the two-stage claim by Novartis — that they invented first Imatinib Mesylate and then β-IM — could not be sustained. Novartis argued before the Supreme Court that Imatinib Mesylate was covered by the Zimmermann Patent (i.e., within its claims) but was not specifically disclosed or taught as a preparation in that patent, and therefore the step of going from Imatinib (the free base) to Imatinib Mesylate involved an inventive step. The respondents, on the other hand, particularly Cipla Ltd. (appearing through Mr. Harish N. Salve, Senior Advocate) and the Union of India, contended that Imatinib Mesylate was fully part of the teaching of the Zimmermann Patent, which disclosed preparing "pharmaceutically acceptable salts" of the compound Imatinib, and that the mesylate salt was an obvious variant known to persons skilled in pharmaceutical chemistry.

The second important sub-dispute was whether the claim for β-IM as a distinct invention could survive the test of Section 3(d) of the 1970 Act. Section 3(d) provides that the "mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance" shall not be considered an invention. The Explanation to Section 3(d) clarifies that salts, esters, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations, and other derivatives of known substances shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy. Novartis argued that β-IM had enhanced efficacy because it had 30% more bioavailability than Imatinib in free-base form, and had better physical properties such as better flow, greater thermodynamic stability, and lower hygroscopicity. The respondents argued that bioavailability improvements and physico-chemical properties were not the same as enhanced therapeutic efficacy as required by Section 3(d), and that Novartis had not produced any research data comparing the therapeutic effect of β-IM with that of Imatinib Mesylate in treating patients.

The third significant dispute related to whether Section 3(d) was an ex majore cautela (out of abundant caution) provision that should be read as subordinate to the general invention tests in Sections 2(1)(j) and 2(1)(ja), or whether it was a substantive, independent test that applied to pharmaceutical substances over and above the tests of novelty and inventive step. Novartis contended that Section 3(d) was merely a precautionary or advisory provision and that if β-IM satisfied the standard tests of novelty and inventive step, Section 3(d) could not stand in the way of granting a patent. The respondents and the courts below had held to the contrary, and this view was ultimately affirmed by the Supreme Court.

A further dispute concerned whether Novartis's own representations in other jurisdictions — particularly before the US Patent Office where it had taken the position that Imatinib Mesylate was taught by the Zimmermann Patent — could bind it before Indian proceedings. The respondents argued that Novartis was blowing hot and cold by claiming in India that Imatinib Mesylate was a new product distinct from Zimmermann while having maintained in the United States that it was fully covered by Zimmermann, and that the principle of estoppel or issue estoppel ought to prevent Novartis from contradicting its own earlier positions.

 

Reasoning and Analysis of the Judges

The Supreme Court delivered a detailed, extensively researched judgment spanning over 100 paragraphs of substantive analysis, touching upon the history of Indian patent law, the international law obligations under TRIPS, the purpose and meaning of Section 3(d), the concept of "invention" and "inventive step" under Indian law, and the factual questions concerning the substance β-IM and its characteristics.

The Court began by examining the legislative history of patent law in India, going back to the pre-independence period and the Patents and Designs Act, 1911. The Judges traced the development of Indian patent law through the Justice Rajagopala Ayyangar Report of 1959, which had strongly recommended that India should not grant product patents in the pharmaceutical sector, and which led to the enactment of the Patents Act, 1970. The Ayyangar Report had specifically noted that allowing product patents in chemicals and pharmaceuticals would lead to monopolies that would be detrimental to public health in a developing country. The Court noted that when Section 5 of the 1970 Act, which barred product patents in drugs and food, was deleted as part of India's TRIPS compliance through the Patents (Amendment) Act, 2005, it was not done in isolation. The deletion of Section 5 was accompanied by the insertion of Section 2(1)(j) and Section 2(1)(ja) — which redefined "invention" and "inventive step" — as well as the amendment to Section 3(d) and the addition of its Explanation, which set up a higher threshold for patentability specifically aimed at pharmaceutical and chemical substances.

The Court quoted from and heavily relied upon Monsanto Co. v. Coramandal Indag Products (P) Ltd., (1986) 1 SCC 642, where the Supreme Court had explained the basic quid pro quo of patent law: an inventor is given a limited monopoly in exchange for publicly disclosing the invention so that at the end of the patent term, the invention falls into the public domain and the public benefits from it. The Court emphasized that the coverage of a patent (what it claims) cannot be wider than its disclosure (what it teaches), and that Patent Law in India should not develop in a direction where the scope of a patent is determined not by the intrinsic worth of the invention but by the clever drafting of claims by skilled lawyers.

On the first major factual question — whether Imatinib Mesylate was a known substance — the Court examined the Zimmermann Patent No. 5,521,184 in considerable detail and concluded that Imatinib Mesylate was indeed a known substance disclosed within that patent. The patent not only taught the use of "pharmaceutically acceptable salts" of Imatinib but also stated the anti-tumoral properties of the compound and its methanesulfonate salt. The Court also noted two published scientific articles from reputed journals — one titled "Inhibition of the Abl Protein-Tyrosine Kinase In Vitro and In Vivo by a 2-Phenylaminopyrimidine Derivative," published in the Cancer Research Journal (Issue January–February 1996) by Dr. Zimmermann himself, and another titled "Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells" published in Nature Medicine (1996) — both of which specifically discussed the anti-tumoral properties of Imatinib and its mesylate salt. The Court observed that in the face of these materials, it was difficult to see how Imatinib Mesylate could be regarded as a new product.

On the question of whether Novartis was bound by its earlier representations, the Court examined the fact that when Novartis obtained US Patent No. 6,894,051 B1 for β-IM, the US Board of Patent Appeals had proceeded on the basis that Zimmermann Patent No. 5,521,184 had the teaching for making of Imatinib Mesylate from Imatinib. The Court held that Novartis, having benefited from this finding and used it in its own case in the United States, was bound by it and could not take a contrary position before Indian courts. Therefore, the development of Imatinib Mesylate from Imatinib did not qualify as an "invention" under Sections 2(1)(j) and 2(1)(ja) of the Patents Act, 1970.

Turning to the second major question — whether β-IM satisfied the test of Section 3(d) — the Court undertook a careful analysis of the meaning of the word "efficacy" as used in that provision. Novartis had argued that "efficacy" should be read broadly to include physico-chemical properties like better flow, thermodynamic stability, lower hygroscopicity, and increased bioavailability, all of which, it was said, made β-IM a better product. The Court rejected this argument with a clear and firm ruling. It held that the word "efficacy" in the context of Section 3(d), when applied to a medicine, must mean "therapeutic efficacy" — that is, the ability of the medicine to produce the desired therapeutic result in treating the disease for which it is prescribed. The Judges relied upon the New Oxford Dictionary of English (1998 edition), the IUPAC Glossary of Terms Used in Medicinal Chemistry (1998), and Goodman and Gilman's pharmacological treatise to establish that in the context of medicines, "efficacy" means therapeutic effectiveness. The Court further examined the Explanation to Section 3(d), which lists salts, polymorphs, and other derivatives as being regarded as the same substance "unless they differ significantly in properties with regard to efficacy," and held that this also pointed to therapeutic efficacy rather than general physicochemical properties.

The Court further reasoned that the legislature had consciously worded the Explanation to specify that properties "inherent" to a form — such as hygroscopicity to a polymorph or solubility to a salt — should not be taken as enhancements in efficacy unless they translate directly into therapeutic gains. Improved bioavailability, by itself, does not necessarily result in better therapeutic outcomes. Novartis had not presented any clinical data, research study, or empirical evidence showing that β-IM was more effective than Imatinib Mesylate in treating CML or any other condition. On the contrary, the drug Gleevec as marketed in India (as well as in the United States) was labelled on its packaging as containing "Imatinib Mesylate Tablets 100 mg" with each film-coated tablet containing "100 mg Imatinib (as Mesylate)." There was no reference at all to β-IM on the packaging. The Court drew the logical inference that if what was actually sold and effective was Imatinib Mesylate — not the β-IM crystalline form specifically — then the patent claim for β-IM was essentially an attempt to monopolise what was, in effect, Imatinib Mesylate, which would otherwise not be patentable. This, the Court noted, was a classic example of what the pharmaceutical industry calls "evergreening."

The Court's analysis on the TRIPS compatibility of Section 3(d) was also significant, though it was largely affirming the High Court's earlier ruling. The Judges held that TRIPS does not define what must constitute an "invention" for patentability; Article 27 of TRIPS requires member states to grant patents for inventions that are new, involve an inventive step, and are capable of industrial application, but it leaves countries free to define the standards for these requirements in their own law. Section 3(d) is India's way of defining that a mere new form of a known pharmaceutical substance, without enhanced therapeutic efficacy, does not qualify as an "invention" for Indian patent law purposes. The Court thus held that Section 3(d) does not violate TRIPS.

The Court also expressed serious concern about the broader implications for patent law development in India. In one of the most quoted paragraphs of the judgment (Paragraph 134), the Court stated that patent law in India should not develop in a manner where the scope of a patent is determined not on the intrinsic worth of the invention but by the artful drafting of claims by skilful lawyers, and where patents are traded as a commodity not for the production and marketing of the patented products but to search for someone who may be sued for infringement of the patent. This was a clear judicial articulation of the philosophy underpinning India's approach to pharmaceutical patents, and it set a strong policy marker for future cases.

The Court further discussed and considered the dichotomy between patent "coverage" and patent "disclosure," relying on several academic treatises including Terrell on the Law of Patents (16th Edition), Chisum on Patents, and academic papers from the Saint Louis University Law Journal. It held that the fundamental rule underlying the grant of patents — that the monopoly granted to the inventor is limited to what he has actually disclosed — means that a patent's coverage cannot exceed its disclosure. This has direct implications for Novartis's claim, since what was disclosed in the Zimmermann Patent (including Imatinib Mesylate) could not be the basis for a new patent merely because a specific crystalline form was now being singled out.

Several judicial decisions from foreign jurisdictions were considered during the course of arguments before the Court, including Plant Genetic Systems, N.V. v. DeKalb Genetics Corpn., 315 F 3d 1335 (Fed Cir 2003); Chiron Corpn. v. Genentech Inc., 363 F 3d 1247 (Fed Cir 2004); A.C. Edwards Ltd. v. Acme Signs & Displays Ltd., 1992 RPC 131; Astellas Pharma Inc. v. Comptroller General of Patents, 2009 EWHC 1916 (Pat); Hogan, In re, 559 F 2d 595 (CCPA 1977); and Glaverbel S.A. v. British Coal Corpn. (No. 2), 1993 RPC 90. These were considered primarily in the context of the relationship between patent coverage and disclosure, though the Court did not mechanically follow foreign precedents in arriving at its conclusion under Indian law.

 

Final Decision of the Court

The Supreme Court, by its unanimous judgment dated April 1, 2013, dismissed the Civil Appeals filed by Novartis AG with costs and held as follows:

The subject product, β-crystalline-Imatinib Mesylate (β-IM), failed both the test of invention as laid down in Sections 2(1)(j) and 2(1)(ja) of the Patents Act, 1970 and the test of enhanced efficacy or patentability under Section 3(d) read with its Explanation. Imatinib Mesylate was found to be a known substance disclosed in the Zimmermann Patent No. 5,521,184. The development of Imatinib Mesylate from Imatinib did not constitute a new invention. β-IM, being a polymorph (a specific crystalline form) of Imatinib Mesylate, was a "new form of a known substance" for the purposes of Section 3(d). Novartis had not demonstrated, through any empirical, clinical, or research data, that β-IM had any enhanced therapeutic efficacy compared to Imatinib Mesylate, the known substance. The improved physical properties of β-IM — such as better flow, thermodynamic stability, lower hygroscopicity, and 30% increased bioavailability — were not sufficient by themselves to constitute "enhanced efficacy" for the purposes of Section 3(d), since efficacy in the context of a medicine means therapeutic efficacy, which must be judged strictly and narrowly. The patent application for β-IM was therefore rightly rejected. The Court upheld R. 55 of Patent Rules, 2003 and held that no violation of Article 21 of the Constitution of India was made out. The appeals filed by Natco Pharma Limited and Cancer Patients Aid Association were allowed to the extent of affirming the rejection of Novartis's patent claim.

 

Point of Law Settled in the Case

This judgment settled several important points of law with lasting significance for Indian patent jurisprudence.

The Supreme Court authoritatively held that "invention" and "patentability" under the Patents Act, 1970 are two distinct and separate concepts. A product may qualify as an "invention" in a general sense and yet may not be patentable if it falls within one of the exclusions in Section 3 of the Act. Section 3(d) is not an ex majore cautela clause but a substantive provision that independently and mandatorily applies to all pharmaceutical and chemical substances of the nature described therein.

The Court settled that in the context of a new form of a known pharmaceutical or chemical substance, the applicant must cumulatively satisfy two tests: first, the invention test under Sections 2(1)(j) and 2(1)(ja), and second, the enhanced therapeutic efficacy test under Section 3(d) read with its Explanation. Both tests must be independently satisfied; clearing one does not exempt the applicant from the other.

The Court definitively interpreted "efficacy" in Section 3(d) as meaning "therapeutic efficacy" in the case of medicines and pharmaceuticals — that is, the ability of the medicine to produce the desired therapeutic effect in treating the disease for which it is prescribed. Physico-chemical properties such as improved flow, better stability, reduced hygroscopicity, or even increased bioavailability, by themselves, do not amount to "enhanced efficacy" unless they are specifically connected to and proven to result in better therapeutic outcomes, which must be established through research or empirical data.

The Court also settled the principle that patent coverage cannot exceed patent disclosure, and that a patent application that draws its very claims and averments from a prior patent (in this case the Zimmermann Patent) while simultaneously claiming to be independent of that prior patent will be critically scrutinized. A party is bound by the positions it has taken and benefited from in foreign proceedings involving the same subject matter.

The ruling firmly placed Section 3(d) as India's principal legislative safeguard against "evergreening" in the pharmaceutical industry — the practice of repeatedly patenting minor modifications of a known drug to extend patent-based monopolies and delay the availability of affordable generic medicines. This was characterized not merely as a matter of patent law but as a matter of public health policy.

 

Case Details

Title: Novartis AG Vs. Union of India and Others (with Natco Pharma Limited v. Union of India and Others, and Cancer Patients Aid Association v. Union of India and Others)

Date of Order: April 1, 2013

Case Numbers: Civil Appeals Nos. 2706-716 of 2013 (Novartis AG); Civil Appeal No. 2728 of 2013 (Natco Pharma Limited); Civil Appeals Nos. 2717-27 of 2013 (Cancer Patients Aid Association) — arising out of SLPs (C) Nos. 20539-49 of 2009, SLP (C) No. 32706 of 2009, and SLPs (C) Nos. 12984-94 of 2013

Neutral Citation / Published Citation: (2013) 6 SCC 1

Court: The Supreme Court of India

Bench: Hon'ble Mr. Justice Aftab Alam and Hon'ble Mrs. Justice Ranjana P. Desai, JJ.

 

Disclaimer: Readers are advised not to treat this as substitute for legal advice as it may contain errors in perception, interpretation, and presentation.

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

 

Suggested SEO Titles

1.    Novartis AG v. Union of India 2013: The Supreme Court Judgment That Changed Pharmaceutical Patent Law in India

2.    Section 3(d) Patents Act Explained: How India Defeated Novartis in the Gleevec Patent Case

3.    Evergreening of Pharmaceutical Patents in India: Lessons from Novartis v. Union of India (2013) 6 SCC 1

4.    Therapeutic Efficacy Test Under Section 3(d) of the Indian Patents Act: The Novartis Gleevec Ruling

5.    Beta-Crystalline Imatinib Mesylate Patent Refused: Supreme Court of India on New Forms of Known Substances

6.    TRIPS Compliance and Indian Patent Law: Analysis of the Novartis Glivec Case

7.    Anti-Evergreening Provision in Indian Patent Law: A Detailed Analysis of (2013) 6 SCC 1

 

SEO Tags

Novartis AG v Union of India, Section 3d Patents Act 1970, Gleevec patent India, Glivec patent case, Imatinib Mesylate patent, beta crystalline Imatinib Mesylate, pharmaceutical patent India, evergreening of patents, therapeutic efficacy test, Indian patent law, Patents Amendment Act 2005, TRIPS and Indian patent law, Supreme Court patent judgment 2013, patent and public health India, Aftab Alam judgment, Ranjana Desai Supreme Court, Zimmermann Patent, Natco Pharma, Cancer Patients Aid Association, new form of known substance, Section 2(1)(j) Patents Act, Section 2(1)(ja) Patents Act, inventive step India, patent eligibility pharmaceutical, product patent India, IPAB judgment patent, patent mailbox India, CML cancer drug patent, affordable medicines India, generic medicines patent, IP law India, intellectual property landmark judgment, patent evergreening prevention, bioavailability patent India, polymorph patent India, AdvocateAjayAmitabhSuman, IPAdjutor

 

Headnote

Novartis AG v. Union of India, (2013) 6 SCC 1 — Supreme Court of India — Bench: Aftab Alam and Ranjana P. Desai, JJ. — Decided on April 1, 2013

Held: Under the Patents Act, 1970 as amended by the Patents (Amendment) Act, 2005, "invention" and "patentability" are distinct concepts, and a substance must satisfy both the general invention test under Sections 2(1)(j) and 2(1)(ja) and the enhanced efficacy test under Section 3(d) in order to qualify for a patent in India. Section 3(d) is a substantive anti-evergreening provision and not a mere precautionary clause. In the case of pharmaceutical and chemical substances, "efficacy" within Section 3(d) means "therapeutic efficacy" — the ability of the medicine to produce the desired therapeutic result in treating the disease — and not merely improved physico-chemical properties. A new crystalline polymorph (beta-crystalline Imatinib Mesylate, β-IM) of a known pharmaceutical substance (Imatinib Mesylate) that does not demonstrate enhanced therapeutic efficacy over the known substance through research/empirical data is not patentable under Indian law. Imatinib Mesylate, being a known substance disclosed in Zimmermann Patent No. 5,521,184 (US), the claim for β-IM also failed the invention test. The drug Gleevec/Glivec (β-IM) marketed and sold as Imatinib Mesylate with no reference to the beta-crystalline form on its packaging indicated a deceptive patent claim. Appeals by Novartis dismissed with costs. Section 3(d) held to be TRIPS-compatible. Patent coverage cannot exceed patent disclosure. Indian Patent Law should not develop in a manner where patents are traded as commodities for litigation rather than for genuine invention and production.